Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Neoadjuvant Nivolumab and Platinum-Doublet Chemotherapy for Early-Stage NSCLC

Efficacy was evaluated in CHECKMATE-816 study
14 Mar 2022
Anticancer agents & Biologic therapy;  Cancer Immunology and Immunotherapy;  Lung and other thoracic tumours

On 4 March 2022, the US Food and Drug Administration (FDA) approved nivolumab (Opdivo, Bristol-Myers Squibb Company) with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting.

This represents the first FDA approval for neoadjuvant therapy for early-stage NSCLC.

Efficacy was evaluated in CHECKMATE-816 (NCT02998528), a randomised, open label study in patients with resectable, histologically confirmed Stage IB (≥4 cm), II, or IIIA NSCLC (AJCC/UICC staging criteria) and measurable disease (RECIST v1.1.). Patients were enroled regardless of the tumour PD-L1 status. A total of 358 patients were randomised to receive either nivolumab plus platinum-doublet chemotherapy administered every 3 weeks for up to 3 cycles, or platinum-chemotherapy alone administered on the same schedule.

The main efficacy outcome measures were event-free survival (EFS) and pathologic complete response (pCR) by blinded independent central review.

Median EFS was 31.6 months (95% confidence interval [CI] 30.2, not reached) in the nivolumab plus chemotherapy arm and 20.8 months (95% CI 14.0, 26.7) for those receiving chemotherapy alone. The hazard ratio was 0.63 (97.38% CI 0.43, 0.91; p = 0.0052). The pCR rate was 24% (95% CI 18.0, 31.0) in the nivolumab plus chemotherapy arm and 2.2% (95% CI 0.6, 5.6) in the chemotherapy alone arm.

The most common adverse reactions (incidence ≥20%) occurring in patients were nausea, constipation, fatigue, decreased appetite, and rash.

The addition of nivolumab to chemotherapy did not result in more frequent delays or cancellations of surgery. The median lengths of hospital stays following definitive surgery and the rates of adverse reactions identified as surgical complications were similar for patients in both arms of the study.

The recommended nivolumab dose is 360 mg with platinum-doublet chemotherapy on the same day every 3 weeks for 3 cycles.

Full prescribing information for Opdivo is available here.

This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence (OCE). Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and the United Kingdom’s Medicines and Healthcare products Regulatory Agency. The application reviews may be ongoing at the other regulatory agencies.

This review used the Real-Time Oncology Review pilot programme, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. The FDA approved this application five months ahead of the FDA goal date.

This application was also granted priority review.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.